Featured
Read our handpicked blogs, curated for you.
|
The Enforcement Horizon: August 2, 2026The industry consensus is dominated by the EU AI Act. As of mid-2026, AI systems…
|
The 2026 Industry Consensus: From Policies to EnforcementThe prevailing consensus among global Tier-1 banks is the…
|
The 2026 Industry Consensus: Unified Systems OrchestrationThe prevailing consensus in 2026 is that "more models…
Recent releases
|
What an HCP Engagement Program Really Means for Indian Pharma
In Indian pharma, budgets are rising but impact often feels invisible. Marketing leaders spend crores across reps, conferences, webinars, and digital campaigns, yet they can’t answer one question…
|
AI in Pharma: From Hype to Actions That Move the Needle
If you’re a pharma CMO in India, here’s the thing: AI in Pharma only pays off when it sits on clean HCP data, pushes compliant content fast, and tells your team exactly what to do next. Anything else…
|
MLR Delays Are Costing You Market Share: How Modular Content Fixes It
Every pharma CMO in India has a war story about MLR delays. Campaigns stuck for weeks because a slide needed a disclaimer. A product launch postponed because promotional material was still circling…
|
Omnichannel in Indian Pharma: From Buzzword to Boardroom ROI
Omnichannel in Indian pharma has become one of those terms every leader throws around in meetings but very few can define in measurable outcomes. Yes, every CMO knows it means “reaching HCPs across…
